CALDEIRÃO DE BOLSA

Vendas do medicamento para a perda de peso Wegovy subiram 67% entre abril e junho.

How Novo Nordisk lost its lead in the weight loss race

Drugmaker struggled to adapt to very high demand and a market where celebrities are more influential than doctors


Until a year ago, Danish drugmaker Novo Nordisk was riding high. It had been first to market with an injectable diabetes treatment and the name Ozempic quickly became shorthand for new class of blockbuster weight loss drugs.

But competition started to catch up, a new drug trial disappointed, shares and growth fell and its chief executive departed in May. Then yesterday a major profit warning knocked more than €60bn off its value. The company also announced that senior executive Maziar Mike Doustdar would become the new CEO.

Some in the industry think Novo’s core problem is quite simple: US rival Eli Lilly came up with a better product. Trials found more weight loss from Lilly’s Mounjaro and Zepbound than Ozempic and another Novo drug Wegovy, and anecdotally doctors report fewer side effects.

(...)

Novo Nordisk shares plunge after profit warning over US weight-loss copycats

Share slide wipes more than €60bn off value of Danish maker of Ozempic and Wegovy

Novo Nordisk has appointed Maziar Mike Doustdar as chief executive and president of the group as it slashed its sales and profit forecasts for the year amid stiff US competition for its blockbuster weight-loss drugs.

(...)

Jørgensen was ousted in May after shares in the company — the maker of Ozempic and Wegovy — fell more than 50 per cent in 12 months. Shares fell more than 26 per cent on Tuesday on the profit warning.

Novo, one of Europe’s largest companies by market capitalisation, said on Tuesday that sales in the first six months of the year rose 18 per cent after the effect of currency fluctuations were stripped out.

But it also warned that full-year sales growth was expected to be 8-14 per cent, sharply lower than its May estimate of 13-21 per cent.
Operating profit grew was up 29 per cent in the first half of the year but Novo said it now expects full-year growth of 10-16 per cent, down from previous estimates of 16-24 per cent.

“For Wegovy in the US, the sales outlook reflects the persistent use of compounded [copycat] GLP-1s, slower than expected market expansion and competition,” the company said.

Novo said in a statement it was pursuing litigation “to protect patients from copycat . . . drugs”.

(...)

A decisão terá sido tomada por mútuo acordo entre Fruergaard Jorgensen e o 'board' da empresa dinamarquesa, avançou a Bloomberg. Entre as causas, é citado o recuo das ações da fabricante de medicamentos nos últimos tempos.

O Governo dinamarquês reviu em forte alta as previsões de crescimento económico para este ano e o próximo à boleia do dinamismo da indústria farmacêutica, em particular da gigante Novo Nordisk.

MarcoAntonio Escreveu:

richardj Escreveu:Cooper: CASE, get ready to match our spin with the retro thrusters.

CASE: It's not possible.

Cooper: No, it's necessary!

Não tem nada que ver com o tópico mas... great line, great movie.

richardj Escreveu:Cooper: CASE, get ready to match our spin with the retro thrusters.

CASE: It's not possible.

Cooper: No, it's necessary!